2Lee AY,LevineMN.Venous thromboembolismand cancer:Risks and outcomes[J].Circulation,2003,107:117
3Stein P,Beemath A,Meyers F,et al.Incidence of venous thromboembolism in patientshospitalized with cancer[J].AmJMed.2006,119:60
4Khorana A,Francis C,Culakova E,et al.Frequency,risk factors,and trends for venousthromboembolism among hospitalized cancer patients[J].Cancer.2007,110:2339
5Geerts W,Pineo G,Heir J,et al.Prevention of venous thromboembolism:The seventh ACCPconference on antithrombotic and thronbolytic therapy[J].Chest,2004,126:338S
6Bergqvist D,Agnelli G,Cohen AT,et al.Duration of prophylaxis against venousthromboembolism with enoxaparin after surgery for accner[J].N Engl J Med,2002,346:975
7Haas SK,Kakkar AK,Kemkes-Mahes B,et al.Prevention of venous thromboembolism withlowmolecularweight heparin in patients with metastatic breast or lung cancer:Results ofthe TOPIC studies[J].J Thromb Haemost.2005,3 (suppll):AbstOR059
8Rajkumar SV,Blood E,Vesole DH,et al.Thalidomide plus dexamethasone versus dexamethasonealone in newly diagnosed multiple myeloma (E1A00):Results of a phase Ⅲ trial coordinatedby the Eastern Cooperative Oncology Group[J].Blood,2004,104:63a
9Gerber DE,Grossman SA,Streiff MB.Management of venous thromboembolism in patients withprimary and matastatic brain tumors[J].J Clin Oncol,2006,24:1310
10Bailer H R,Agnelli G,Hull R,et al.Antithrombotic therapy for venous thromboembolicdisease:The seventh ACCP conference on antithrombotic and thrombolytictherapy[J].Chest,2004,126:401s
